Research map: Final analysis of the FeDeriCa phase III study: long-term efficacy, safety and pharmacokinetics of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection, plus chemotherapy, in HER2-positive early breast cancer

Back to the article

Papers in this map

  1. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene · Dennis J. Slamon · 1987 · 11847 citations · Cited by this paper
  2. 61eP Radiotherapy combined with PARP inhibition in BRCA-mutated breast cancer: A systematic review of clinical outcomes and toxicity · 2026 · Related
  3. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update · Antonio C. Wolff · 2013 · 4103 citations · Cited by this paper
  4. Nectin-4 and Trop-2 expression in collecting duct carcinoma: new promising therapeutic targets · 2026 · Related
  5. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial · Luca Gianni · 2011 · 2403 citations · Cited by this paper
  6. 149P Adjuvant radiotherapy outcomes for early stage (stage 1c-2) clear cell ovarian carcinoma in Edinburgh cancer centre · 2026 · Related
  7. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer · Gϋnter von Minckwitz · 2017 · 1429 citations · Cited by this paper
  8. 213P Glandular tissue–based versus anatomical landmark–based CTV delineation in postoperative breast cancer radiotherapy: A dosimetric comparison · 2026 · Related
  9. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) · Andreas Schneeweiß · 2013 · 1312 citations · Cited by this paper
  10. 194eP Ovarian cancer during pregnancy: Maternal and fetal outcomes from a systematic review and meta-analysis · 2026 · Related
  11. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study · Sandra M. Swain · 2013 · 1012 citations · Cited by this paper
  12. 67RO Single-cell and TCR profiling reveals pre-existing cytotoxic CD8 T cell clonal expansion and peripheral–tumor dissociation associated with response to PD-1-based therapy in hepatocellular carcinoma · 2026 · Related
  13. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial · Sara A. Hurvitz · 2017 · 548 citations · Cited by this paper
  14. 219P Clinical profile and treatment outcomes of lymphoma patients: A retrospective cohort study · 2026 · Related
  15. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial · Gustavo Ismael · 2012 · 352 citations · Cited by this paper
  16. A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma) · 2026 · Related
  17. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study · Sandra M. Swain · 2017 · 256 citations · Cited by this paper
  18. 152P Efficacy and safety of relacorilant + nab-paclitaxel in patients aged ≥65 years with platinum-resistant ovarian cancer (PROC) in the phase III ROSELLA study (GOG-3073, ENGOT-ov72, APGOT-Ov10) · 2026 · Related
  19. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study · Xavier B. Pivot · 2013 · 233 citations · Cited by this paper
  20. 232eP GLP-1 receptor agonists and risk of incident endometrial, colorectal, and hepatocellular cancer: A systematic review and meta-analysis · 2026 · Related
  21. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study · Xavier B. Pivot · 2014 · 178 citations · Cited by this paper
  22. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study · Antoinette R. Tan · 2020 · 175 citations · Cited by this paper
  23. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial · Sibylle Loibl · 2016 · 120 citations · Cited by this paper
  24. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER 2‐positive early breast cancer · E De Cock · 2016 · 111 citations · Cited by this paper
  25. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study · Joyce A O'Shaughnessy · 2021 · 82 citations · Cited by this paper
  26. Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer · Christian Jackisch · 2019 · 81 citations · Cited by this paper
  27. HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up · Christian Jackisch · 2016 · 80 citations · Cited by this paper
  28. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain · Guillermo López-Vivanco · 2017 · 54 citations · Cited by this paper
  29. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study · Xavier B. Pivot · 2017 · 51 citations · Cited by this paper
  30. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients · Joseph Gligorov · 2017 · 47 citations · Cited by this paper
  31. Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer · Hannelore G Denys · 2020 · 44 citations · Cited by this paper
  32. Flexible care in breast cancer · Andrew M. Wardley · 2021 · 30 citations · Cited by this paper
  33. White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example · Christian Jackisch · 2022 · 25 citations · Cited by this paper
  34. Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study · Sherko Küemmel · 2021 · 23 citations · Cited by this paper
  35. Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study · Bei Wang · 2021 · 18 citations · Cited by this paper
  36. Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial) · Adrienne Gropper Waks · 2024 · 16 citations · Cited by this paper
  37. 1MO The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina study · Zhi‐Ming Shao · 2022 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)